EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Medpace Holdings's enterprise value is $11,831 Mil.
Medpace Holdings's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was $381 Mil. Therefore, Medpace Holdings's EV-to-EBITDA for today is 31.02.
The historical rank and industry rank for Medpace Holdings's EV-to-EBITDA or its related term are showing as below:
MEDP'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 10.83 Med: 20.79 Max: 46.72
Current: 31.02
During the past 11 years, the highest EV-to-EBITDA of Medpace Holdings was 46.72. The lowest was 10.83. And the median was 20.79.
MEDP's EV-to-EBITDA is ranked worse than 83.76% of 117
companies
in the Medical Diagnostics & Research industry
Industry Median: 16.18
vs MEDP: 31.02
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Medpace Holdings EV-to-EBITDA Historical Data
The historical data trend for Medpace Holdings's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Medpace Holdings's EV-to-EBITDA
For the Diagnostics & Research subindustry, Medpace Holdings's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medpace Holdings's EV-to-EBITDA Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Medpace Holdings's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Medpace Holdings's EV-to-EBITDA falls into.
Medpace Holdings's current Enterprise Value is $11,831 Mil.
Medpace Holdings's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $381 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Medpace Holdings's PE Ratio for today is calculated as:
Medpace Holdings's share price for today is $393.355.
Medpace Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $9.810.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Medpace Holdings's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Medpace Holdings (Medpace Holdings) Business Description
Medpace is a late-stage contract research organization, or CRO, that provides full-service drug development and clinical trial services to small and midsized biotechnology, pharmaceutical, and medical device firms. Medpace also offers ancillary services such as bio-analytical laboratory services and imaging capabilities. The company was founded over 30 years ago, and it has over 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are principally based in the U.S., but it also operates in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in February 2014, and it exited Medpace in August 2018.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
MEDP has been successfully added to your 